经口腔前庭入路内镜甲状腺切除术治疗甲状腺癌:单术者150例结局与手术完整性
单术者前瞻性收集、回顾性分析150例经口腔前庭入路内镜甲状腺切除术(TOETVA)与125例开放甲状腺切除术(OT)的甲状腺癌患者,比较临床病理、并发症及全甲状腺切除的血清甲状腺球蛋白(Tg)水平。TOETVA组年龄更轻、女性占96.7%,全甲状腺切除比例较低,手术时间更长,但清扫淋巴结数目及刺激后Tg水平与OT组无显著差异。TOETVA在选定甲状腺癌患者中可行,肿瘤学安全,但需大样本前瞻性队列研究含复发监测进一步证实。
要点
- TOETVA组与OT组清扫淋巴结数目在腺叶切除和全甲状腺切除中均无显著差异。
- 全甲状腺切除后刺激后Tg水平两组无显著差异,TOETVA组80.0%患者刺激后Tg低于1.0 ng/ml。
- TOETVA手术时间在腺叶切除和全甲状腺切除中均长于OT组。
核心结论
- TOETVA在选定甲状腺癌患者中可行,不仅美容优势,且肿瘤学安全。
- 需大样本前瞻性队列研究包含复发监测以巩固TOETVA的可行性。
研究设计与样本
- 单术者前瞻性收集数据、回顾性分析,2016年8月至2019年3月纳入150例TOETVA和125例OT甲状腺癌患者。
- 比较临床病理发现、并发症及全甲状腺切除病例的血清Tg水平以评估手术完整性。
主要发现
- TOETVA组平均年龄43.06±10.90岁,OT组51.02±12.42岁;TOETVA组女性占96.7%。
- 全甲状腺切除比例OT组65.0%高于TOETVA组26.7%。
- 腺叶切除手术时间TOETVA组102.12±32.59 min,OT组76.38±21.24 min;全甲状腺切除TOETVA组132.65±34.79 min,OT组90.71±25.09 min。
- 最大肿瘤直径TOETVA组0.91±1.00,OT组1.19±1.07。
- 清扫淋巴结数目腺叶切除TOETVA组3.19±2.89 vs OT组3.49±2.41(p=0.319),全甲状腺切除4.98±3.12 vs 5.70±4.35(p=0.714)。
临床怎么用
- TOETVA可作为选定甲状腺癌患者的美容替代术式,需注意手术时间较长。
- 全甲状腺切除后可通过刺激后Tg水平评估手术完整性,TOETVA组80.0%患者低于1.0 ng/ml。
局限性
- 回顾性分析,非随机对照。
- 需大样本前瞻性队列研究包含复发监测进一步证实。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Transoral endoscopic thyroid surgery vestibular approach (TOETVA) is a promising technique involving no skin incision. Since its first use in 60 patients in 2015, TOETVA has been adopted by several hospitals worldwide. However, reports of TOETVA for thyroid cancer are scarce. METHODS: Between August 2016 and March 2019, 150 and 125 thyroid cancer patients underwent TOETVA and open thyroidectomy (OT), respectively, by a single endocrine surgeon. Comparative analyses were performed on clinical and pathological findings, complications, and surgical completeness in total thyroidectomy cases, as indicated by the serum thyroglobulin (Tg) level. Data were collected prospectively and analyzed retrospectively. RESULTS: Mean age was younger in the TOETVA than in the OT group (43.06 ± 10.90 vs. 51.02 ± 12.42). The percentage of females was 96.7% in the TOETVA group. Total thyroidectomy was higher in the OT group (26.7% vs. 65.0%). Operation time (min) was longer in the TOETVA group for lobectomy (102.12 ± 32.59 vs. 76.38 ± 21.24) and total thyroidectomy (132.65 ± 34.79 vs. 90.71 ± 25.09). The largest tumor diameter was 0.91 (± 1.00) in the TOETVA group and 1.19 (± 1.07) in the OT group. The harvested lymph node number was not significantly different between the two groups for lobectomy (3.19 ± 2.89 vs. 3.49 ± 2.41, p = 0.319) and total thyroidectomy (4.98 ± 3.12 vs. 5.70 ± 4.35, p = 0.714). The thyroid-stimulating hormone stimulated Tg level before administration of the first dose of radioactive iodine was also not different (3.38 ± 10.87 vs. 3.44 ± 11.51, p = 0.595). Percentage of stimulated Tg below 1.0 ng/ml was 80.0% in the TOETVA group. CONCLUSIONS: TOETVA is feasible in selected thyroid cancer patients, not only because it is cosmetically advantageous but also because it is oncologically safe. A large prospective cohort study including recurrence surveillance is needed to consolidate the feasibility of TOETVA.
引用
- Ahn JH, Yi JW. Transoral endoscopic thyroidectomy for thyroid carcinoma: outcomes and surgical completeness in 150 single-surgeon cases. Surg Endosc. 2019. PMID: 31139987. doi:10.1007/s00464-019-06841-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。